

## SEQUENCE LISTING

<110> GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

<120> CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE

<130> 220721

<150> 60/360,543

<151> 2002-02-27

<150> 60/370,189

<151> 2002-04-05

<160> 24

<170> PatentIn version 3.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 1

Phe Ala Leu Ala  
1

<210> 2

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 2

Val Leu Ala Leu Ala  
1 5

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 3

Ala Leu Ala Leu  
1

<210> 4

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 4

Ala Leu Ala Leu Ala  
1 5

<210> 5

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 5

Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys Lys  
1 5 10 15

Gln Gly Pro Trp Leu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp  
20 25 30

Phe

<210> 6

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc\_feature

<222> (2)..(2)

<223> Xaa = at position 2 is norleucine

<400> 6

Trp Xaa Asp Phe  
1

<210> 7

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> xaa = at position 2 is sulfotyrosine

<400> 7  
Asp Xaa Met Gly Trp Met Asp Phe  
1 5

<210> 8  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic  
<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> xaa = at position 2 is sulfotyrosine

<220>  
<221> misc\_feature  
<222> (3)..(3)  
<223> xaa = at position 3 is norleucine

<220>  
<221> misc\_feature  
<222> (6)..(6)  
<223> xaa = at position 6 is norleucine

<400> 8

Asp Xaa Xaa Gly Trp Xaa Asp Phe  
1 5

<210> 9  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic  
<400> 9

Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro  
1 5 10 15

Arg Gly Asn His Trp Ala Val Gly His Leu Met  
20 25

<210> 10  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic  
<400> 10  
Trp Ala Val Gly His Leu Met  
1 5

<210> 11  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic  
<400> 11

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
1 5 10

<210> 12

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc\_feature

<222> (1)..(8)

<223> wherein the peptide is carboxylated at either the N-or C- terminus

<400> 12

Phe Cys Phe Trp Lys Thr Cys Thr  
1 5

<210> 13

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 13

Arg Pro Leu Pro Gln Gln Phe Phe Gly Leu Met  
1 5 10

<210> 14

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 14

Pro Gly Thr Cys Glu Ile Cys Ala Tyr Ala Ala Cys Thr Gly Cys  
1 5 10 15

<210> 15

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 15

Asn Asp Asp Cys Glu Leu Cys Val Ala Cys Thr Gly Cys Leu  
1 5 10

<210> 16

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 16

Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Phe  
1 5 10 15

<210> 17

<211> 29

<212> PRT

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 17

His Ser Asp Ala Leu Phe Thr Asp Asn Tyr Thr Arg Leu Arg Leu Gln  
1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn Gly  
20 25

&lt;210&gt; 18

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (17)..(17)

&lt;223&gt; xaa = at position 17 is norleucine

&lt;400&gt; 18

His Ser Asp Ala Leu Phe Thr Asp Asn Tyr Thr Arg Leu Arg Leu Gln  
1 5 10 15

xaa Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn Gly  
20 25

&lt;210&gt; 19

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;220&gt;

<221> misc\_feature  
<222> (5)..(5)  
<223> Xaa = at position 5 is norleucine

<400> 19

Ala Tyr Gly Trp Xaa Asp Phe  
1 5

<210> 20  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Synthetic  
<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> Xaa = at position 8 is norleucine

<400> 20

Glu Glu Glu Ala Tyr Gly Trp Xaa Asp Phe  
1 5 10

<210> 21  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic  
<220>  
<221> misc\_feature

<222> (1)..(1)

<223> xaa = at position 1 is 2-cyclohexyl-L-alanine

<400> 21

Xaa Leu Ala Leu Ala  
1 5

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc\_feature

<222> (1)..(1)

<223> xaa = at position 1 is 2-cyclohexyl-L-alanine

<220>

<221> misc\_feature

<222> (2)..(2)

<223> xaa = at position 2 is 2-cyclohexyl-L-alanine

<400> 22

Xaa Xaa Leu Ala Leu  
1 5

<210> 23

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> Xaa = at position 1 is 1-naphtyl-alanine

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> Xaa = at position 2 is 2-cyclohexyl-L-alanine

<400> 23  
Xaa Xaa Leu Ala Leu  
1 5

<210> 24  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> Xaa = at position 1 is 1-naphtyl-alanine

<400> 24  
Xaa Leu Ala Leu Ala  
1 5